Home › Hairloss Labs › JAK Inhibitors for Alopecia: 2026 Guidance and Trial Data

Hairloss Labs · Treatments

JAK Inhibitors for Alopecia: 2026 Guidance and Trial Data

JAK inhibitors for alopecia areata explained: the 2026 US expert consensus, baricitinib's new teen approval, trial results side by side, and safety monitoring.

By Scott Blaine Hoffman · November 19, 2026 · 7 min read

JAK inhibitors are daily prescription tablets that quiet the immune signals attacking hair follicles in alopecia areata. As of November 2026, three are FDA-approved for severe alopecia areata, and the first US expert consensus, published in JAMA Dermatology in September 2026, now names them the primary long-term treatment for adults with severe disease. They can regrow substantial hair for many people, but not for everyone, and they need ongoing medical monitoring.

Key takeaways
  • Approved options: baricitinib (adults, and since September 25, 2026, adolescents 12 and older), ritlecitinib (12 and older) and deuruxolitinib (adults).
  • In the pivotal trials, roughly 23% to 42% of people on the approved doses reached 80% or more scalp coverage within 24 to 36 weeks, versus under 1% to 6% on placebo.
  • The new US guidance says to allow at least 6 months before judging whether a drug is working.
  • All three carry FDA boxed warnings and require blood tests before and during treatment.

What changed in 2026

Two developments reshaped how dermatologists talk about these drugs this autumn.

1. The first US treatment consensus for severe alopecia areata

The National Alopecia Areata Foundation and the American Hair Research Society brought together 31 US hair specialists for a three-round Delphi survey (May to November 2025), built on a systematic review of the literature through December 2024. A recommendation needed 70% agreement. The result, Gregoire, Dewey and colleagues, JAMA Dermatology 2026, makes these points for adults with severe alopecia areata:

Severity in the guidance is measured on the Alopecia Areata Scale: 50% to 100% scalp loss is severe, and milder disease can be moved up a level if eyebrows or eyelashes are involved, quality of life is badly affected, or 6 months of treatment has not helped. The recommendations do not cover children, pregnancy, mild or moderate disease, or people with significant other health conditions.

2. Baricitinib approved for teenagers

On September 25, 2026, the FDA extended baricitinib to people aged 12 and older with severe alopecia areata. The approval rests on BRAVE-AA-PEDS, the first phase 3 trial built specifically for younger patients with severe disease. In its main cohort, 257 adolescents (median baseline: complete scalp loss, average disease duration 6.4 years) were randomized to 4 mg, 2 mg or placebo. At week 36, 42% on 4 mg and 27% on 2 mg reached 80% or more scalp coverage, versus 5% on placebo (Dermatology Times report of the approval).

The three approved drugs side by side

This table pulls the pivotal-trial results into one place. "SALT 20 or less" means no more than 20% of the scalp still bald, roughly 80% coverage or better.

Drug (approval)WhoApproved dosingPivotal trial result: SALT 20 or less
Baricitinib (June 2022; teens Sept 2026)Adults and ages 12+2 mg once daily, 4 mg if needed (4 mg may be used from the start with near-total loss)Week 36, adults: 38.8% and 35.9% on 4 mg, 22.8% and 19.4% on 2 mg, 6.2% and 3.3% on placebo (BRAVE-AA1 and AA2, about 1,200 patients)
Ritlecitinib (June 2023)Ages 12+50 mg once dailyWeek 24: 23% on 50 mg vs about 2% on placebo (ALLEGRO phase 2b/3, 718 patients including 105 adolescents)
Deuruxolitinib (July 2024)Adults8 mg twice dailyWeek 24: 29.6% on 8 mg vs 0.8% on placebo (THRIVE-AA1, 706 patients; a 12 mg arm reached 41.5% but that dose is not approved)

Sources: BRAVE-AA trials, NEJM 2022; ritlecitinib trial, Lancet 2023; THRIVE-AA1, JAAD 2024.

Why you can't rank them from this table

It is tempting to read the highest number as the best drug. The trials were not designed for that. They measured success at different weeks (24 versus 36), enrolled somewhat different patients and were run years apart. There are still no head-to-head trials, and the JAMA Dermatology panel lists "which drug for which patient" as an open question. In practice the choice often comes down to age, other health conditions, other medicines you take, insurance coverage and dosing convenience.

What the newest pooled analysis adds

A systematic review and meta-analysis in the American Journal of Clinical Dermatology (Morriss and colleagues, 2026) combined 12 randomized trials with 4,141 participants aged 12 and older. Compared with placebo, oral JAK inhibitors made reaching SALT 20 or less at week 24 about eight times more likely (odds ratio 7.99). Any side effect was more common on the drugs (odds ratio 1.60), but serious adverse events and stopping because of side effects were not significantly different from placebo.

The limits matter. Half the trials had "some concerns" for risk of bias, serious events were too few for stable estimates, only one trial enrolled adolescents, and trials last months while real-world treatment may last years. Reassuring short-term trial safety does not settle long-term risk.

Safety and monitoring

JAK inhibitors as a class carry FDA boxed warnings for serious infections (including tuberculosis), death, cancer, major heart events and blood clots. Much of that warning comes from data in older adults with rheumatoid arthritis and cardiovascular risk factors, a different population from most people with alopecia areata, but it applies to the whole class and is taken seriously.

The deuruxolitinib prescribing information gives a typical picture of the monitoring involved:

Deuruxolitinib has one extra rule: it must not be used by people whose genes make them poor CYP2C9 metabolizers or by those taking moderate or strong CYP2C9 inhibitors, so a genetic test is part of starting it. None of these drugs should be combined with other JAK inhibitors, biologic immune drugs or strong immunosuppressants.

What to expect if you start

  1. Months 0 to 3: blood tests, then often little visible change. This is normal.
  2. Months 3 to 6: regrowth, if it comes, usually starts to show.
  3. Month 6 onward: the decision point under the new guidance. A partial response may justify continuing to 12 months, a dose change or a switch.
  4. Long term: for people who respond, treatment is generally continued at the same dose, with regular monitoring.

Because JAK inhibitors treat an active immune process, they are a different question from hair transplants, which are generally not advised while alopecia areata is active. Our alopecia areata guide covers that, along with injections and other options for smaller patches. While waiting for regrowth, many people use wigs or hairpieces, and the panel endorsed letters supporting insurance coverage for them.

When to see a doctor

See a board-certified dermatologist if you notice round bald patches, rapid or widespread loss, loss of eyebrows or eyelashes, or nail pitting. Seek prompt care for scalp pain, redness or scaling, which can signal a scarring condition such as frontal fibrosing alopecia. If you already take a JAK inhibitor, contact your prescriber right away about fever or signs of infection, chest pain, shortness of breath, or leg swelling or pain. Our guide to seeing a dermatologist for hair loss explains what the visit involves.

FAQ

Do JAK inhibitors work for male or female pattern baldness?

They are not approved for it, and the hormone-driven process behind pattern hair loss is different from the immune attack in alopecia areata. For pattern loss, see our articles on minoxidil and dutasteride.

Can I use a JAK inhibitor cream instead of tablets?

The 2026 panel did not recommend topical JAK inhibitors for the scalp because of limited evidence. It did accept them as an option for eyebrows, eyelashes and beard.

Will my hair stay if I stop?

Not reliably. The guidance advises continuous treatment for responders, and how to taper safely is still being studied. Never stop or change the dose without talking to your prescriber.

Questions about your own situation? Ask our team or browse more research in Hairloss Labs.

Talk it through before you decide

Ask Hairloss AI, powered by Regrowth Intelligence, about your own pattern and the questions to bring to a consultation. When you're ready, find a vetted hair restoration specialist near you.

Sources

By Scott Blaine Hoffman, founder of Regrowth.com, 30+ years in the hair-loss field. Published November 19, 2026 in Hairloss Labs.

Educational information, not medical advice. Talk to a doctor or dermatologist about your own hair loss before starting or stopping any treatment.

Hairloss Labs

More from Hairloss Labs

Evidence-based articles on hair loss, treatments and hair restoration, reviewed against medical sources.

See every article in Hairloss Labs →